CoChat
Sign Up
Cited by 155Bone Metabolism and DiseasesBone health and osteoporosis researchEstrogen and related hormone effects

Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation.

Ishida, Yoichiro, Heersche, Johan N. M.·1998·Journal of Bone and Mineral Research
DOI 10.1359/jbmr.1998.13.12.1822
Open this paper in CoChat — free account

Abstract

Since hench et al.(1) first reported the use of cortisone for treatment of patients with rheumatoid arthritis, glucocorticoids (GCs) have been widely used for anti-inflammatory and immunosuppressive therapy. However, GCs have major effects on several organ systems, including the cardiovascular, endocrine, gastrointestinal, ophthalmic, and musculoskeletal systems, and these often lead to major side effects.(2) Among the most dramatic side effects of in vivo long-term GC excess is the development of GC-induced osteoporosis.(3, 4) Several lines of evidence indicate that the major mechanisms whereby GCs induce osteoporosis are decreased bone matrix deposition by osteoblasts, stimulation of osteoclastic bone resorption, and decreased intestinal calcium resorption with resulting mild secondary hyperparathyroidism (for reviews see Refs. 3, 5–8). However, the diverse and complex effects of GCs on bone metabolism are still incompletely understood, mainly due to differences in experimental outcomes in different systems and culture conditions, which could be a result of species differences, age of the experimental animals used, maturation stage of the cells studied, heterogeneity of osteoblast populations, differences between transformed cells and normal cells, or length and dose of GC treatment used. In this brief review, we will focus on the effects of GCs on bone formation. With regard to this aspect of GC effects, it has been reported in a variety of in vitro systems that GCs induce cells of the osteoblast lineage to differentiate into mature cells expressing the osteoblastic phenotype, e.g., parathyroid hormone–stimulated cAMP synthesis, osteopontin, bone sialoprotein, alkaline phosphatase (AP), and mineralized bone nodule formation.(9-22) However, in several in vitro systems, GCs have also been shown to decrease type I collagen synthesis and mRNA levels,(23-25) osteocalcin production and mRNA levels,(24, 26, 27) and the expression of insulin-like growth factor I (IGF-I)(28-30) and selected IGF-binding proteins (IGFBPs) which enhance IGF activity (e.g., IGFBP-3 and IGFBP-5).(31, 32) The reason for the observed differences is not clear, but it is known that the GC receptor can mediate not only transcriptional activation but also repression of transcriptional expression by interfering with the binding or activity of other transcription factors(33) or by interacting directly with negative glucocorticoid response elements (nGREs).(34) For example, the GC-induced inhibition of 1,25-dihydroxyvitamin D3–mediated osteocalcin transcription is likely to occur by binding of the GC receptor to a nGRE overlapping the TATA box in the proximal promoter region of osteocalcin gene.(35) In addition, mRNA levels can also be controlled by GCs through selective changes in mRNA stability.(36, 37) Indeed, Delany et al.(25) have shown that GC-mediated down-regulation of α1(I) collagen mRNA occurs by a decrease in the stability of α1(I) collagen mRNA in bone cell populations derived from fetal rat calvariae. Although a number of such mechanisms for negative-transcriptional or post-transcriptional gene regulation by GCs have been described, it is still unclear in many systems how positive and negative regulation interact to result in the observed effects (for review see Ref. 38). Furthermore, the observed differences may well be related to the fact that the effects of GCs are often dependent on the timing of GC treatment and the stage of differentiation of the osteoblast-like cells used. For example, when cultures obtained from chick embryo calvariae were continuously exposed to dexamethasone (Dex) from the onset of culture, Dex increased AP activity, but when Dex was added late in the culture period after bone had formed, AP activity decreased.(11) In addition, Dietrich et al.(39) have shown that in fetal rat calvariae, 30–100 nM cortisol stimulated collagen synthesis after 24 h, while inhibitory effects of 1 μM cortisol were seen at 48–96 h. In vivo data uniformly indicate that GCs stimulate bone resorption and decrease bone formation, resulting in bone loss.(40-42) It is important to note, however, that the inhibitory effects reported in vivo are generally seen only at pharmacological doses of the GCs used. With regard to the naturally circulating forms of GCs, some species secrete predominantly cortisol (man, guinea pig, and rabbit) and others corticosterone (mouse and rat).(43) GC receptors of cortisol-secreting species (man, guinea pig, and rabbit) bind cortisol with a much higher affinity than corticosterone, whereas GC receptors of corticosterone-secreting species (rat, mouse) bind corticosterone with a much higher affinity than cortisol.(44) The data of Table 1 show relative GC binding affinities and biological potencies of various GCs in rat and man published in separate papers by several authors. In both human and animal studies, various GCs have been used, e.g., corticosterone, cortisol, cortisone, prednisone, prednisolone, or

Integrity signals

Registry

Crossref · 10.1359/jbmr.1998.13.12.1822

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ishida, Y., & Heersche, J. N. M.
Affiliations
  • Yamaguchi University (JP)
  • University of Toronto (CA)
Corresponding author
Ishida, Yoichiro
Venue
Journal of Bone and Mineral Research
Publisher
Oxford University Press (OUP)
Published
1998-12-01
Volume
13
Issue
12
Pages
1822-1826
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
DOI
10.1359/jbmr.1998.13.12.1822
OpenAlex
W2058566062
Cited by
155
References
84
Citations by year
2026: 3 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 6 · 2012: 5
FWCI
0.60
Type
journal article
Language
en
Open access
closed
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Journal of Bone and Mineral Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
glucocorticoid-induced osteoporosis, glucocorticoids, osteogenic differentiation, bone formation, osteoblast lineage, type I collagen synthesis, osteocalcin, insulin-like growth factor I, IGF binding proteins, glucocorticoid receptor, transcriptional repression, bone matrix deposition, glucocorticoid adverse effects, alkaline phosphatase, osteopontin, bone sialoprotein, osteoblast maturation
MeSH terms
Animals, Cell Differentiation, Dose-Response Relationship, Drug, Glucocorticoids, Humans, Osteoblasts, Osteogenesis, Osteoporosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review